Safety and Efficacy Study of NGGT002 in PKU Adult Subjects

Summary

This is a single-center, open-label, non-randomized, dose escalation study to evaluate the safety, tolerability and efficacy of NGGT002 in adult Phenylketonuria (PKU) subjects. All subjects will receive a single administration of NGGT002 and will be followed for safety and efficacy for 5 years.

Timeline

Start

2023-03-30

Primary completion

2028-12-30

Completion

2028-12-30

Drugs

Indications